Widespread availability of real-world data has enabled the generation of evidence and insights that benefit patients, providers, plans, and industry. Explore our real-world data analyses to support your strategic decisions.
Avalere will empower expanded insight and improvement in outcomes for value-based diabetes medications, using Inovalon’s data resources and advanced value-based care platforms.
Earlier this year, Avalere led a work group of rheumatology, orthopedic surgery, psychiatry, sports medicine, and primary care clinicians to develop appropriate use criteria for the use of hyaluronic acid (HA) in the treatment of knee osteoarthritis (OA).
Avalere recently partnered with the Alliance for Home Health Quality and Innovation (AHHQI) to explore the topic of the future of home health care.
Results from a new Avalere study will be presented Thursday, October 27, at the 30th Annual North American Cystic Fibrosis Conference in Orlando, Florida.
Recently we examined the various models of specialty pharmacy integration/ownership and how they result in different care coordination dynamics and access to drugs. Our findings demonstrate real value and opportunities in linking medical and pharmacy data to better support the patient journey with services and tools.
Hepatitis C and Oncology Are Top Therapeutic Area Targets
Christie Teigland, PhD, vice president, Advanced Analytics, recently received the Academy of Managed Care Pharmacy’s (AMCP) prestigious Platinum Award for her research entitled “Association of Socioeconomic and Clinical Factors with Rates of High-Risk Medication Use in Medicare Advantage Plans.”
On behalf of The Pew Charitable Trusts, Avalere conducted research to identify current barriers to interoperability and some of the best potential solutions in the current political and business environments.
To what extent do patients currently have access to their own data in their providers’ electronic health records, and what does the future hold for consumer access to their digital health data? Listen to Avalere's Josh Seidman share how far we’ve come with providing patients access to their health data, where there is still room for improvement, and what patients can expect to see in the future.
A new analysis by Avalere examines differences in Medicare spending for episodes of care before and after cardiovascular imaging, colonoscopy, and evaluation and management services. Avalere applied a risk adjustment methodology to account for differences in patient demographics and patient severity across settings. The findings suggest when care is initiated in the typically higher-paying HOPD setting than in physicians' offices and ambulatory surgical centers, the services that follow also result in higher spending relative to when care is initiated in the office setting.
Our final webinar in a three-part series: Navigating the New Dynamics of Outcomes Contracting and Risk Sharing Arrangements covers: Key considerations for designing effective Performance Contracts; current therapeutic areas of focus between Payers and Pharma; ways to better align data collection and outcomes measurement; considerations to address key regulatory and compliance challenges; and various financial incentive models that can govern these arrangements.
In the second of our three-part series of webinars on Navigating the New Dynamics of Outcomes Contracting and Risk Sharing Arrangements, we cover: Examples of performance contracting from both the US and EU5; important lessons learned from first generation arrangements; key considerations for aligning payers and manufacturers on incentives, measures, and data collection; and characteristics of good payer and manufacturer partners.
New research from Avalere Health finds that 86% of pharmaceutical companies would invest more in studies to support the development of healthcare economic information if provided additional guidance on their ability to use this evidence with external audiences.
Avalere hosts a series of webinars on “Navigating the New Dynamics of Outcomes Contracting and Risk Sharing Arrangements”. While traditional rebating and discounting terms have been a staple of industry contract negotiations, a new strategic focus is emerging on additional modes through which overall value can be measured for the wave of high-cost drugs now coming to shore.
With the rise in state-based and regional comparative effectiveness research (CER), local CER programs like the New England Comparative Effectiveness Review Public Advisory Council (CEPAC) have become increasingly influential in payer decision making.
New Avalere research for The SCAN Foundation demonstrates the ROI potential of well-targeted care coordination programs supported by robust data.
Many of Avalere's experts are heading north to Canada for ISPOR's 19th Annual International Meeting, where we'll have several panel discussions and poster presentations.